In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion

Emerged mutations can be attributed to increased transmissibility of the B.1.617 and B.1.36 Indian delta variants of SARS‐CoV‐2, most notably substitutions L452R/E484Q and N440K, respectively, which occur in the receptor‐binding domain (RBD) of the Spike (S) fusion glycoprotein.

[1]  Ravindra K. Gupta,et al.  SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion , 2021, The Journal of infectious diseases.

[2]  G. Vaidyanathan.  Coronavirus variants are spreading in India — what scientists know so far , 2021, Nature.

[3]  M. Vogel,et al.  Molecular definition of SARS-CoV-2 RBD mutations: receptor affinity versus neutralization of receptor interaction , 2021 .

[4]  M. Suchard,et al.  Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil , 2021, Science.

[5]  M. Vogel,et al.  BNT162b2 mRNA COVID‐19 vaccine induces antibodies of broader cross‐reactivity than natural infection, but recognition of mutant viruses is up to 10‐fold reduced , 2021, bioRxiv.

[6]  M. Zamani,et al.  Mutations in SARS-CoV-2; Consequences in structure, function, and pathogenicity of the virus , 2021, Microbial Pathogenesis.

[7]  A. Godzik,et al.  Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.

[8]  Weiliang Zhu,et al.  Predicting the Potential Effect of E484K Mutation on the Binding of 28 Antibodies to the Spike Protein of SARS-CoV-2 by Molecular Dynamics Simulation and Free Energy Calculation , 2021 .

[9]  Vineet D. Menachery,et al.  Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera , 2021, Nature Medicine.

[10]  A. García-Sastre,et al.  The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. , 2021, medRxiv.

[11]  J. Marschall,et al.  Accuracy of serological testing for SARS‐CoV‐2 antibodies: First results of a large mixed‐method evaluation study , 2020, Allergy.

[12]  I. Wilson,et al.  A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody , 2020, bioRxiv.

[13]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals , 2020, bioRxiv.

[14]  K. Yuen,et al.  Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 , 2020, Cell.

[15]  Rejane L Petersen.  Strategies Using Bio-Layer Interferometry Biosensor Technology for Vaccine Research and Development , 2017, Biosensors.